Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies

References

• Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin. Oncol.34(6 Suppl. 4), S17–S23 (2007).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol.10(9), 872–876 (2009).
   PubMed Web of Science ®Google Scholar
• Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur. Urol.49(3), 429–440 (2006).
   PubMed Web of Science ®Google Scholar
• Lipton A. Emerging role of bisphosphonates in the clinic – antitumor activity and prevention of metastasis to bone. Cancer Treat. Rev.34(Suppl. 1), S25–S30 (2008).
   Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer2(8), 584–593 (2002).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer110(8), 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol.16(4), 579–584 (2005).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason D, Murray R et al. Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases [poster]. Presented at: 19th Annual EAU Congress. Vienna, Austria, 24–27 March 2004 (Abstract 615).
   Google Scholar
• Major PP, Cook RJ, Chen BL, Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support. Cancer Ther.2(4), 234–240 (2005).
   PubMedGoogle Scholar
• Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei Y-J. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin. Lung Cancer6(3), 170–174 (2004).
   PubMedGoogle Scholar
• Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer100(12), 2613–2621 (2004).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96(11), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Cereceda LE, Flechon A, Droz J-P. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin. Prostate Cancer2(1), 34–40 (2003).
   PubMedGoogle Scholar
• Lipton A, Small E, Saad F et al. The new bisphosphonate, Zometa® (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest.20(Suppl. 2), 45–54 (2002).
   PubMed Web of Science ®Google Scholar
• Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev.34(2), 183–192 (2008).
   PubMed Web of Science ®Google Scholar
• Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol.21(23), 4277–4284 (2003).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason D, Murray R et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster]. Presented at: American Urological Association Annual Meeting. Chicago, IL, USA, 26 April–1 May 2003 (Abstract 1472).
   Google Scholar
• Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur. Urol.53(1), 68–80 (2008).
   PubMed Web of Science ®Google Scholar
• DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support. Care Cancer15(7), 869–876 (2007).
   PubMed Web of Science ®Google Scholar
• Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol.26(15), 2544–2549 (2008).
   PubMed Web of Science ®Google Scholar
• Oudard S, Banu E, Medioni J et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int.103(12), 1641–1646 (2009).
   Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J. Natl Cancer Inst.95(17), 1300–1311 (2003).
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer113(1), 193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Body J-J, Cook R, Costa L et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Presented at: The IX International Meeting on Cancer Induced Bone Disease. Arlington, VA, USA, 28–31 October 2009 (Abstract 71).
   Google Scholar
• Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer6, 15–23 (2006).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Risks and benefits of bisphosphonates. Br. J. Cancer98(11), 1736–1740 (2008).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int.96(7), 964–969 (2005).
   PubMed Web of Science ®Google Scholar
• Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int. J. Clin. Oncol.15(4), 382–389 (2010).
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360(7), 679–691 (2009).
   PubMed Web of Science ®Google Scholar
• Coleman R, Bundred N, De Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December 2009 (Abstract 4082).
   Google Scholar
• Felix J, Andreozzi V, Soares M et al. Treatment costs of skeletal-related events (SRE) in patients with metastatic breast or prostate cancer [abstract]. Eur. J. Cancer Suppl.5(Suppl.), 172 (2007) (Abstract 1241).
   Google Scholar
• Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur. Urol.43(3), 226–232 (2003).
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am. J. Manag. Care14(5), 317–322 (2008).
   PubMed Web of Science ®Google Scholar
• Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J. Oncol. Pharm. Pract.13(4), 223–229 (2007).
   PubMedGoogle Scholar
• Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol.139(1), 101–111 (2005).
   PubMed Web of Science ®Google Scholar
• Dieli F, Vermijlen D, Fulfaro F et al. Targeting human {γ}δ} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res.67(15), 7450–7457 (2007).
   PubMed Web of Science ®Google Scholar
• Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist10(1), 52–62 (2005).
   PubMed Web of Science ®Google Scholar
• Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol.42(11), 1228–1236 (2002).
   PubMed Web of Science ®Google Scholar
• Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs64(11), 1197–1211 (2004).
   PubMed Web of Science ®Google Scholar
• Mehrotra B. Safety profile of intravenous bisphosphonates. Semin. Oncol.34(6 Suppl. 4), S24–S27 (2007).
   Google Scholar
• Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am. Soc. Hematol. Educ. Program356–360, 515 (2006).
   Google Scholar
• Weitzman R, Sauter N, Eriksen EF et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients – May 2006. Crit. Rev. Oncol. Hematol.62(2), 148–152 (2007).
   PubMed Web of Science ®Google Scholar
• Henry D, von Moos R, Vadhan-Rja S et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [oral presentation]. Presented at: Joint ECCO 15–34th ESMO Multidisciplinary Congress. Berlin, Germany, 24–27 September 2009 (Abstract 20LBA).
   Google Scholar
• Stopeck A, Body JJ, Fujiwara Y et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized Phase 3 study [oral presentation]. Presented at: Joint ECCO 15–34th ESMO Multidisciplinary Congress. Berlin, Germany, 24–27 September 2009 (Abstract 2LBA).
   Google Scholar
• Fizazi K, Carducci MA, Smith MR et al. A randomized Phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol.28(Suppl. 18) (2010) (Abstract LBA4507).
   Google Scholar
• Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res.23(6), 826–836 (2008).
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol.20(1), 137–145 (2009).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol.20(1), 117–120 (2009).
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Maniezzo M, Ghiringhelli R et al. Medical ozone oil suspension applications heal osteonecrosis of the jaws (ONJs) in patients treated with bisfosfonates (BPs). Preliminary results of a single institution protocol. Breast18(Suppl. 1), S67–S68 (2009) (Abstract 0194).
   Google Scholar
• Nelson WG. New therapeutic targets and treatments for metastatic prostate cancer. In: Prostate Cancer: 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases. McConnell J, Abrams P, Denis L (Eds). Health Publications, Paris, France, 309–346 (2006).
   Google Scholar
• Saad F, Higano CS, Sartor O et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin. Genitourin. Cancer4(4), 257–262 (2006).
   PubMed Web of Science ®Google Scholar
• Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol.19(3), 420–432 (2008).
   PubMed Web of Science ®Google Scholar
• Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer (review). Cochrane Database Syst. Rev.4, CD006250 (2006).
   Google Scholar
• Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized Phase II trial. J. Urol.182(2), 509–515 (2009).
   PubMed Web of Science ®Google Scholar
• Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int.103(4), 434–440 (2009).
   PubMed Web of Science ®Google Scholar
• Hannon RA, Clack G, Rimmer M et al. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase I trial. J. Bone Miner. Res.25(3), 463–471 (2010).
   PubMed Web of Science ®Google Scholar
• Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin. Investig. Drugs19(5), 605–614 (2010).
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat. Rev.36(2), 177–184 (2010).
   PubMed Web of Science ®Google Scholar
• Shazer RL, Jain A, Galkin AV et al. Raloxifene, an oestrogen-receptor-β-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot Phase II clinical trial. BJU Int.97(4), 691–697 (2006).
   Google Scholar
• Parker C, Hoskin P, Pascoe S et al. A double-blind, randomised, dose finding, Phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005-003680-22 [abstract]. Eur. J. Cancer Suppl.7(Suppl.), 406 (2009) (Abstract O-7003).
   Google Scholar
• Drake CG, Antonarakis ES. Update: immunological strategies for prostate cancer. Curr. Urol. Rep.11(3), 202–207 (2010).
   Google Scholar
• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16), 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar